Breaking News, Collaborations & Alliances

LegoChem, Takeda Enter ADC Cancer Research Collaboration

Will focus on the development of antibody drug conjugates in immuno-oncology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

LegoChem Biosciences has entered a research collaboration and license agreement with Takeda for the development of antibody-drug conjugates (ADCs) in immuno-oncology.   Takeda gains certain rights to LegoChemi’s ADC technology, ConjuAll, including its proprietary linker and conjugation platform, to research, develop and commercialize targeted immuno-oncology therapeutics. Under the terms of the agreement, Takeda has rights to use the LegoChem technology to develop therapeutics directed to up to ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters